Published in Cardiovascular Business Week, April 13th, 2004
Lexipafant is under late stage development for protection from organ dysfunction associated with coronary artery bypass graft (CABG), the treatment of HIV associated cognitive/motor dysfunction, and as a treatment for patients with acute pancreatitis. DevCo also announced that protocols and clinical trial material have been prepared and are available for an immediate start of phase III programs.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.